Novo Nordisk CEO: The Disclosure Of An Additional 4,000 Personnel Leaving The Company Brings Total Corporate Downsizing Related To The Operational Unification To 13,000 Individuals

It Is Time To Further Diversify The Company We're Creating A New Segment Called Blood And Endocrine Disorder Liver Disease Is Also An Obvious Place For Us To Go Cardiovascular Is Another Obvious Place For Us To Go, Despite Recent Setbacks